Entries by arcticnovartis

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis
Mon, 09/16/2024 – 10:19

Read more about Novartis Kisqali® shows deepening…

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
arcticnovartis
Wed, 08/28/2024 – 07:19

Read more about Novartis twice-yearly* Le…

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis
Thu, 08/08/2024 – 01:34

Read more about Novartis receiv…

Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 

Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 
arcticnovartis
Mon, 07/29/2024 – 18:04

Read more about Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly …

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Thu, 07/18/2024 – 07:03

Read more about Novartis erzielt im zweiten Quarta…

Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024

Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
arcticnovartis
Thu, 07/18/2024 – 07:03

Read more about Novartis a poursuivi…

Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance

Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
arcticnovartis
Thu, 07/18/2024 – 07:03

Read more about Novartis continues to deliver strong sales growth and core margin expansi…

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Fri, 05/31/2024 – 14:19

Read more about Latest analysis of Novartis NAT…

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04

Read more about Novartis Scembl…

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Fri, 05/31/2024 – 00:04

Read more about Novartis Phase III data confirm sustained efficacy and long-term s…